Table 5.

Histological features associated with CS cholangiocyte marker expression (univariate analysis).

	Regression coefficient	95% CI	p value
p16 in NBD
HA	0.39	0.07 to 0.93	0.025
BDL	0.25	−0.08 to 0.76	0.107
Fibrosis	0.49	0.26 to 0.89	0.001
Stage	0.43	0.17 to 0.81	0.003
MH	0.26	−0.05 to 0.59	0.093
DR	0.22	−0.08 to 0.51	0.148
p16 in DR
HA	0.27	−0.05 to 0.87	0.082
BDL	0.34	0.13 to 0.97	0.012
Fibrosis	0.69	0.57 to 1.11	<0.001
Stage	0.58	0.38 to 0.99	<0.001
MH	0.51	0.25 to 0.84	0.001
DR	0.54	0.29 to 0.82	<0.001
p21 in NBD
HA	0.46	0.26 to 1.26	0.004
BDL	0.50	0.33 to 1.28	0.001
Fibrosis	0.29	0.18 to 0.99	0.006
Stage	0.45	0.18 to 0.99	0.006
MH	0.54	0.26 to 0.92	0.001
DR	0.46	0.18 to 0.90	0.004
p21 in DR
HA	0.28	−0.03 to 0.93	0.068
BDL	0.33	0.05 to 0.95	0.030
Fibrosis	0.53	0.34 to 1.01	<0.001
Stage	0.49	0.27 to 0.94	0.001
MH	0.57	0.35 to 0.95	<0.001
DR	0.59	0.36 to 0.89	<0.001

BDL, bile duct loss; CS, cellular senescence; DR, ductular reaction; HA, hepatitis activity; MH, metaplastic hepatocytes; NBD, native bile duct; p16, p16^INK4A; p21, p21^WAF1/Cip1. In Bold p values < 0.05.